SyneuRx International (Taiwan) Corp   Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (2013)

Organization Overview

First Clinical Trial
2014
NCT01908192
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

SyneuRx International (Taiwan) Corp

Active Ingredients

Drugs in Phase 3 Trials (1)

naben (3 trials)

Drugs in Phase 2 Trials (1)

Pentarlandir (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2